Use of Radioactive Iodine for Thyroid Cancer and Risk for Second Primary Malignancy: A Nationwide Population-Based Study

Journal of the National Cancer Institute

Volumn 108, Issue 2, 2016, Pages

  Teng, Chung Jen ^a,b,c   Hu, Yu Wen ^b,c   Chen, San Chi ^b,c   Yeh, Chiu Mei ^b   Chiang, Huey Ling ^a,d   Chen, Tzeng Ji ^b,c   Liu, Chia Jen ^b,c  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RISK; COLON CANCER; COMORBIDITY; DRUG USE; FEMALE; HUMAN; KIDNEY CANCER; LEUKEMIA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM CANCER; NONHODGKIN LYMPHOMA; PANCREAS CANCER; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION HAZARD; RECTUM CANCER; SECOND CANCER; TAIWAN; THYROID CANCER; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; FOLLOW UP; INCIDENCE; KIDNEY NEOPLASMS; LUNG NEOPLASMS; LYMPHOMA, NON-HODGKIN; MEDIASTINAL NEOPLASMS; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; ODDS RATIO; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; RISK; THYROID NEOPLASMS; TIME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; IODINE RADIOISOTOPES; KIDNEY NEOPLASMS; LEUKEMIA; LUNG NEOPLASMS; LYMPHOMA, NON-HODGKIN; MALE; MEDIASTINAL NEOPLASMS; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; ODDS RATIO; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RADIOTHERAPY DOSAGE; RISK; TAIWAN; THYROID NEOPLASMS; TIME FACTORS;

EID: 84962557490     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv314     Document Type: Article

References (38)

1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295(18):2164-2167.
2. Kilfoy BA, Zheng T, Holford TR, et al. International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control. 2009;20(5):525-531.
3. Veiga LH, Neta G, Aschebrook-Kilfoy B, et al. Thyroid cancer incidence patterns in Sao Paulo, Brazil and the U.S. SEER program, 1997-2008. Thyroid. 2013;23(6):748-757.
4. Eheman C, Henley SJ, Ballard-Barbash R, et al. Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer. 2012;118(9):2338-2366.
5. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15, 698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer. 1997;79(3):564-573.
6. Lundgren CI, Hall P, Ekbom A, et al. Incidence and survival of Swedish patients with differentiated thyroid cancer. Int J Cancer. 2003;106(4):569-573.
7. Lundgren CI, Hall P, Dickman PW, Zedenius J. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer. 2006;106(3):524-531.
8. Lu CH, Lee KD, Chen PT, et al. Second primary malignancies following thyroid cancer: a population-based study in Taiwan. Eur J Endocrinol. 2013;169(5):577-585.
9. Canchola AJ, Horn-Ross PL, Purdie DM. Risk of second primary malignancies in women with papillary thyroid cancer. Am J Epidemiol. 2006;163(6):521-527.
10. Berthe E, Henry-Amar M, Michels JJ, et al. Risk of second primary cancer following differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2004;31(5):685-691.
11. Ronckers CM, McCarron P, Ron E. Thyroid cancer and multiple primary tumors in the SEER cancer registries. Int J Cancer. 2005;117(2):281-288.
12. Sandeep TC, Strachan MW, Reynolds RM, et al. Second primary cancers in thyroid cancer patients: a multinational record linkage study. J Clin Endocrinol Metab. 2006;91(5):1819-1825.
13. Subramanian S, Goldstein DP, Parlea L, et al. Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. Thyroid. 2007;17(12):1277-1288.
14. Lee SL. Radioactive iodine therapy. Curr Opin Endocrinol Diabetes Obes. 2012;19(5):420-428.
15. Sawka AM, Thabane L, Parlea L, et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid. 2009;19(5):451-457.
16. Brown AP, Chen J, Hitchcock YJ, et al. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab. 2008;93(2):504-515.
17. Rubino C, de Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer. 2003;89(9):1638-1644.
18. Iyer NG, Morris LG, Tuttle RM, et al. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer. 2011;117(19):4439-4446.
19. de Vathaire F, Schlumberger M, Delisle MJ, et al. Leukaemias and cancers following iodine-131 administration for thyroid cancer. Br J Cancer. 1997;75(5):734-739.
20. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16(2):109-142.
21. Tuttle RM, Leboeuf R, Robbins RJ, et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med. 2006;47(10):1587-1591.
22. Mandel SJ, Mandel L. Radioactive iodine and the salivary glands. Thyroid. 2003;13(3):265-271.
23. Cheng TM. Taiwan's new national health insurance program: genesis and experience so far. Health Aff (Millwood). 2003;22(3):61-76.
24. National Comprehensive Cancer Network. Thyroid Carcinoma (Version 1.2015). http://www.nccn.org/professionals/physician-gls/pdf/thyroid.pdf. Accessed 28 May, 2015.
25. Pacini F, Castagna MG, Brilli L, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii110-119.
26. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
27. Breslow NE, Day NE. Statistical methods in cancer research. Volume II - The design and analysis of cohort studies. IARC Sci Publ. 1987;(82):1-406.
28. Korn EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol. 1997;145(1):72-80.
29. Noshchenko AG, Zamostyan PV, Bondar OY, Drozdova VD. Radiationinduced leukemia risk among those aged 0-20 at the time of the Chernobyl accident: a case-control study in the Ukraine. Int J Cancer. 2002;99(4):609-618.
30. Fisher LD, Lin DY. Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health. 1999;20:145-157.
31. Liu CJ, Hu YW. Immortal time bias in retrospective analysis: Is there a survival benefit in patients with glioblastoma who received prolonged treatment of adjuvant valganciclovir? Int J Cancer. 2014;135(1):250-251.
32. Hall P, Boice JD Jr, Berg G, et al. Leukaemia incidence after iodine-131 exposure. Lancet. 1992;340(8810):1-4.
33. Weinberg RA. The action of oncogenes in the cytoplasm and nucleus. Science. 1985;230(4727):770-776.
34. Monteiro Gil O, Oliveira NG, Rodrigues AS, et al. Cytogenetic alterations and oxidative stress in thyroid cancer patients after iodine-131 therapy. Mutagenesis. 2000;15(1):69-75.
35. Erselcan T, Sungu S, Ozdemir S, et al. Iodine-131 treatment and chromosomal damage: in vivo dose-effect relationship. Eur J Nucl Med Mol Imaging. 2004;31(5):676-684.
36. Eidemuller M, Ostroumova E, Krestinina L, et al. Comparison of mortality and incidence solid cancer risk after radiation exposure in the Techa River Cohort. Radiat Environ Biophys. 2010;49(3):477-490.
37. Haut ER, Pronovost PJ. Surveillance bias in outcomes reporting. JAMA. 2011;305(23):2462-2463.
38. Ron E, Lubin JH, Shore RE, et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res. 1995;141(3):259-277.